Literature DB >> 12374659

The surgical management of metastatic melanoma.

Peter J Allen1, Daniel G Coit.   

Abstract

When deciding whether or not to perform a resection for metastatic melanoma, one should follow general principles that apply to the patient with melanoma as well as to the patient with metastases from other types of primary tumors. When the resection is palliative, the success of surgical treatment will be governed by the presence of identifiable symptoms, the morbidity of the procedure, the course of the disease, and the ability to communicate treatment goals among surgeon, patient, and family. When the resection is performed with curative intent, long-term survival depends on the ability of the surgeon to select patients with a pattern of recurrence suggestive of a less aggressive tumor biology. Regardless of the extent of the operative procedure, resection of metastases in patients whose disease recurs early after the treatment of the primary tumor, in those who present with multiple lesions, and in those who present with disease that cannot be completely resected will only rarely be associated with subsequent long-term survival.

Entities:  

Mesh:

Year:  2002        PMID: 12374659     DOI: 10.1007/BF02574498

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

Review 1.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

2.  Selected patients with metastatic melanoma may benefit from liver resection.

Authors:  Paulo Herman; Marcel Autran C Machado; André Luis Montagnini; Luiz A C D'Albuquerque; William A Saad; Marcel C C Machado
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

3.  A 20-year experience of hepatic resection for melanoma: is there an expanding role?

Authors:  Mark B Faries; Anna Leung; Donald L Morton; Danielle Hari; Ji-Hey Lee; Myung-shin Sim; Anton J Bilchik
Journal:  J Am Coll Surg       Date:  2014-05-10       Impact factor: 6.113

4.  Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.

Authors:  Valentine Heidelberger; François Goldwasser; Nora Kramkimel; Anne Jouinot; Nathalie Franck; Jennifer Arrondeau; Sarah Guégan; Audrey Mansuet-Lupo; Jérôme Alexandre; Diane Damotte; Marie-Françoise Avril; Nicolas Dupin; Sélim Aractingi
Journal:  Invest New Drugs       Date:  2017-05-31       Impact factor: 3.850

Review 5.  Therapy for metastatic melanoma: the past, present, and future.

Authors:  Laura Finn; Svetomir N Markovic; Richard W Joseph
Journal:  BMC Med       Date:  2012-03-02       Impact factor: 8.775

6.  Variant on Manifestation of Duodenal Metastasis 26 Years after Initial Diagnosis of Primary Cutaneous Melanoma.

Authors:  Kumiko Kitajima; Armelle Bardier-Dupas; Sylvie Breton; Géraldine Rousseau; Jean-Michel Siksik; Jean-Christophe Vaillant; Laurent Hannoun
Journal:  Case Rep Gastroenterol       Date:  2010-03-17

7.  Non-squamous cell carcinoma of the penis: single-center, 15-year experience.

Authors:  Kelvin A Moses; John P Sfakianos; Andrew Winer; Melanie Bernstein; Paul Russo; Guido Dalbagni
Journal:  World J Urol       Date:  2013-12-01       Impact factor: 4.226

Review 8.  Optimal management of metastatic melanoma: current strategies and future directions.

Authors:  Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

9.  Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.

Authors:  Ferdinando C M Cananzi; Satvinder Mudan; Mary Dunne; Nneka Belonwu; Angus G Dalgleish
Journal:  Hum Vaccin Immunother       Date:  2013-07-09       Impact factor: 3.452

10.  Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera.

Authors:  Lynn T Dengel; Craig L Slingluff
Journal:  J Surg Oncol       Date:  2009-11-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.